GLP-1RAs shown to reduce risk of cardiovascular death
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) such as semaglutide, liraglutide, and tirzepatide are widely prescribed both for Type 2 diabetes and weight loss. These drugs also have shown promise in clinical trials for patients with chronic cardiovascular, kidney, and metabolic diseases. Those studies focused mainly on patients with singular diagnoses, but these conditions often overlap.
Struggling with chronic stress? Wellness coach shares 7 nutrients to lower cortisol and boost GLP-1 naturally
Chronic stress not only makes you feel overwhelmed but can also deplete key nutrients and mess with hormones. Rachel shares 7 nutrients that can help.
2 FTSE 100 shares I like better than Rolls-Royce right now
Over the past three years, Rolls-Royce (LSE:RR) shares have mounted the sort of comeback story normally reserved for Hollywood movies. It has certainly benefitted my portfolio, reminding me that FTSE 100 stocks can also sometimes serve up Tesla-type returns. However, while I’m still bullish long term, the market appears well up to date with the […]
Can Ozempic trigger depression or suicidal thoughts? Australia weighs in
Australia has issued a safety alert on GLP-1 drugs after reviewing reports of depression and suicidal thoughts; while there is no proven causal link, regulators want users to stay alert
Cal-Maine Foods, Inc. (CALM): A Bull Case Theory
We came across a bullish thesis on Cal-Maine Foods, Inc. on Fallacy Alarm’s Substack by Rene Bruentrup. In this article, we will summarize the bulls’ thesis on CALM. Cal-Maine Foods, Inc.’s share was trading at $83.63 as of December 1st. CALM’s trailing P/E was 3.20 according to Yahoo Finance. TZIDO SUN/Shutterstock.com Cal-Maine Foods (CALM), the largest egg producer […]
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with Alzheimer’s disease, investors and researchers got the first look at the actual data from the studies, which were presented at the Clinical Trials on Alzheimer’s Disease 2025 meeting.
Dumb AI, Golden Yuan, & Q-Day Comes Early: Here Are Saxo’s Outrageous Prediction For 2026
Dumb AI, Golden Yuan, & Q-Day Comes Early: Here Are Saxo’s Outrageous Prediction For 2026 The future almost never arrives in straight lines. Whether its’ technology, culture, or politics, changes and evolution often come slowly from year to year. But then, suddenly, there is a lurch. Saxo’s Outrageous Predictions live in those lurches. They are […]
Ozempic for cats? New drug could help obese cats
Could this be the Ozempic for cats? A pharmaceutical company is testing a GLP-1 device that may help cats lose weight. READ: https://www.usatoday.com/story/pets-animals/cat/2025/12/04/overweight-cats-weight-loss-glp-1/87601817007/
Hims & Hers launches into Canada as country prepare for generic GLP-1 weight loss drugs
Hims & Hers launched in Canada after announcing the company completed its all-cash acquisition of Canadian digital health provider “Livewell”. The deal comes just one month before generic semaglutide weight loss drugs come to market in the country. Brandon Gomez spoke exclusively with CEO Andrew Dudum about the deal and what it means for the […]
GLP-1 Receptor Agonist Use Linked to Chronic Cough Among Adults With Type 2 Diabetes
THURSDAY, Dec. 4, 2025 — For patients with type 2 diabetes, there is an association between glucagon-like peptide-1 receptor agonist (GLP-1 RA) use and chronic cough, according to a study published online Nov. 26 in JAMA Otolaryngology-Head &…